Drugs / Amcenestrant
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05126329 | Nov 2021 → May 2022 | liver disorder | Sanofi | Terminated | No outcome recorded |
| Phase 1 | NCT04940026 | Jun → Aug 2021 | breast cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03816839 | Mar 2019 → Oct 2020 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03284957 | Sep 2017 → Nov 2024 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04191382 | Feb 2020 → Apr 2021 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT04059484 | Oct 2019 → Feb 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 2 | NCT01042379 | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05128773 | Feb → Oct 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT04478266 | Oct 2020 → Jun 2022 | breast cancer | Sanofi | Terminated | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-08-17 | Sanofi | Press Release: Sanofi provides update on amcenestrant clinical development program sanofi.com ↗ |
| 2022-03-14 | Sanofi | Press Release: Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer sanofi.com ↗ |
| 2021-06-04 | Sanofi | Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer sanofi.com ↗ |
| 2021-05-19 | Sanofi | Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer sanofi.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Amcenestrant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05128773 ↗ |
| Known as | SAR439859 | “Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer” NCT04059484 ↗4“Amcenestrant (SAR439859), 200mg QD, p.o.” NCT01042379 ↗ “Drug: Amcenestrant (SAR439859)” NCT04191382 ↗ “Amcenestrant (SAR439859)” NCT03816839 ↗ |
| Action | Deplete | “Estrogen receptor alpha degrader” CHEMBL4475463 ↗ |
| Action | Inhibit | “Paired tumor biopsy and cell-free DNA analyses revealed ER inhibition and degradation” PMID 35840573 ↗ Jul 2022 |
| Modality | Other / unclassified | “selective estrogen receptor degrader (SERD)” PMID 36977973 ↗ Mar 2023 |
| Route | Oral | “Amcenestrant (SAR439859), 200mg QD, p.o.” NCT01042379 ↗ |
| Target | ESR1 | “Estrogen receptor alpha degrader” CHEMBL4475463 ↗ |